Katowice, Poland, 13 June 2025 — On May 28, AnchorMan® Left Atrial Appendage Closure System (AnchorMan®), developed by MicroPort® CardioAdvent, a subsidiary of MicroPort® CardioFlow, was successfully used in its first post-market application in EU, at the prestigious Medical University of Silesia in Katowice, Poland, marking a key milestone in its global deployment.
The procedure was performed by Dr. Wojtek Wojakowski and his team at the Medical University of Silesia. The device was successfully implanted, with no intraoperative or post-operative complications observed.
AnchorMan® is designed to address a wide range of anatomical challenges in Left Atrial Appendage Closure (LAAC) procedures. Compared with conventional open and closed left atrial appendage occludes, the AnchorMan® LAAC system integrates the advantages of both. Its semi-closed structure, featuring 12 “3D folding” units and an advanced frame design, addresses key challenges associated with deep sheath placement in conventional plug-in closure systems while ensuring stable anchoring. The device’s soft, rounded distal end minimizes trauma to LAA tissue, while its dense NiTi alloy frame design ensures tight conformity to the LAA anatomy, providing superior sealing performance. Additionally, its two deployment options - advancement and unsheathing - offer physicians more flexibility during procedures.
Following the procedure, Dr. Wojtek Wojakowski noted the system’s short learning curve and intuitive operability. He also highlighted its unique 3D folded, rounded distal design, which contributes to a streamlined implantation process.
AnchorMan® received CE MDR certification in February 2025. “AnchorMan® represents a new generation of LAAC technology, combining innovative design with practical performance in the clinical setting,” said Mr. Zhang Ruinian, President of MicroPort® CardioFlow, “its introduction to the European market marks a significant step in expanding access to innovative treatment options.”
Mr. Chen Guoming, Chairman of MicroPort® CardioFlow, added: "Over the past year, two of our flagship products — VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System and AnchorMan® — have successively obtained the stringent CE MDR certification. Together, they reflect our commitment to advancing next-generation technologies in the treatment of structural heart disease.”
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation, HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic research and development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/